DENTSPLY SIRONA (NASDAQ:XRAY) Issues Earnings Results

DENTSPLY SIRONA (NASDAQ:XRAY) announced its quarterly earnings results on Thursday. The medical instruments supplier reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.35 by $0.17, FiscalAI reports. The firm had revenue of $898.00 million during the quarter, compared to analysts’ expectations of $889.93 million. DENTSPLY SIRONA had a negative net margin of 17.06% and a positive return on equity of 18.83%. The company’s revenue for the quarter was down 4.1% compared to the same quarter last year. During the same quarter last year, the company posted $0.52 earnings per share. DENTSPLY SIRONA updated its FY 2026 guidance to 1.400-1.500 EPS.

Here are the key takeaways from DENTSPLY SIRONA’s conference call:

• Q2 revenue declined: Sales fell 4.1% as reported, or 6.3% on a constant-currency basis, with weakness in CAD/CAM, dental consumables, implants and SureSmile. Adjusted EPS was flat at $0.52, while adjusted EBITDA margins were roughly unchanged only after a $44 million tariff refund.
• DENTSPLY SIRONA maintained its 2026 outlook for revenue of $3.5 billion–$3.6 billion and adjusted EPS of $1.40–$1.50, excluding tariff-related effects. Management expects Q3 revenue and earnings to decline sequentially because of seasonality and planned investments.
• The company said the U.S. recovery remains its top priority, but commercial-force training and dealer expansion are expected to have a larger impact in 2027 rather than this year. Management also acknowledged that the U.S. is currently lagging competitors in implants and that SureSmile remains pressured.
• Management reported progress on its 24-month Return-to-Growth plan, including expanded dealer partnerships, clinical education, sales-force certification and increased R&D investment, with improvements expected to become more visible in Q4. DS Core adoption and double-digit APAC milling-system growth were cited as encouraging signs.
• Wellspect remained a bright spot, with revenue up 7.1% on continued new-product sales and geographic expansion. Operating cash flow rose to $99 million from $48 million, and the company repurchased 1.3 million shares while continuing to prioritize debt reduction.

DENTSPLY SIRONA Stock Performance

Shares of NASDAQ:XRAY traded down $0.61 during trading on Thursday, reaching $13.17. 5,502,740 shares of the stock were exchanged, compared to its average volume of 5,046,330. DENTSPLY SIRONA has a 12 month low of $9.40 and a 12 month high of $14.86. The stock has a 50-day moving average price of $11.68 and a 200-day moving average price of $11.88. The company has a current ratio of 1.53, a quick ratio of 0.98 and a debt-to-equity ratio of 1.52. The firm has a market cap of $2.64 billion, a PE ratio of -4.18, a PEG ratio of 1.70 and a beta of 0.85.

Analyst Upgrades and Downgrades

A number of research firms recently commented on XRAY. Piper Sandler lifted their price target on DENTSPLY SIRONA from $13.00 to $14.00 and gave the stock a “neutral” rating in a report on Wednesday, July 29th. Citigroup assumed coverage on DENTSPLY SIRONA in a research note on Wednesday, April 15th. They issued a “sell” rating and a $10.00 price objective on the stock. Barclays reduced their target price on DENTSPLY SIRONA from $12.00 to $9.00 and set an “underweight” rating for the company in a research note on Thursday, June 4th. Mizuho decreased their target price on DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. Finally, UBS Group dropped their price target on DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. Three equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, DENTSPLY SIRONA has an average rating of “Hold” and a consensus target price of $13.46.

Insider Transactions at DENTSPLY SIRONA

In other news, Director Michael J. Barber acquired 15,175 shares of the firm’s stock in a transaction on Thursday, June 11th. The shares were purchased at an average cost of $9.88 per share, with a total value of $149,929.00. Following the acquisition, the director directly owned 55,943 shares in the company, valued at $552,716.84. This represents a 37.22% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Brian P. Mckeon acquired 10,000 shares of the stock in a transaction on Friday, June 12th. The shares were purchased at an average price of $10.12 per share, for a total transaction of $101,200.00. Following the transaction, the director directly owned 10,000 shares in the company, valued at approximately $101,200. This trade represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have bought 35,160 shares of company stock worth $351,179. Company insiders own 0.46% of the company’s stock.

Hedge Funds Weigh In On DENTSPLY SIRONA

Institutional investors and hedge funds have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of DENTSPLY SIRONA during the first quarter worth approximately $26,000. Goldman Sachs Group Inc. boosted its stake in shares of DENTSPLY SIRONA by 827.3% in the first quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock valued at $36,378,000 after buying an additional 2,172,343 shares during the period. Empowered Funds LLC grew its position in DENTSPLY SIRONA by 8.8% during the first quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier’s stock worth $244,000 after buying an additional 1,320 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in DENTSPLY SIRONA by 7.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 593,021 shares of the medical instruments supplier’s stock worth $8,860,000 after acquiring an additional 41,579 shares during the period. Finally, Focus Partners Wealth raised its holdings in DENTSPLY SIRONA by 59.1% in the 1st quarter. Focus Partners Wealth now owns 25,181 shares of the medical instruments supplier’s stock valued at $376,000 after acquiring an additional 9,355 shares in the last quarter. 95.70% of the stock is currently owned by institutional investors and hedge funds.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.